Drug-ELuting REGistry: ReAl-World Treatment of LesioNs in the Peripheral VasCulaturE - ELEGANCE
||Boston Scientific Corporation
||Male and Female Patients
|U.S. Govt. ID:
||Kate Dalton: 347-514-3366 / email@example.com
This study is to collect information about the symptoms and treatments of patient who have severely clogged arteries and treated with commercially available Boston Scientific Corporation drug-eluting devices marketed for treatment of lesions located in the peripheral vasculature. If you choose to be part of this research, we will ask you to be involved in office visits at 6, 12, and 24 months as well as follow-up at 36, 48, and 24 months will be completed in office or remotely. Your involvement in the research will last for 5 years. There are no or minimal risks from participating in this study. There are no physical risks associated with this study. We will take measures to maintain the confidentiality of all study participants, however, accidental disclosure of your medical information is a potential risk. The study may have no benefits to you directly. You have the alternative of not taking part in this study.
Sahil Parikh, MD
|Are you 18 years or older?
|Are you scheduled for a cardiac catheterization at Columbia University Medical Center?